Health - Jun 14
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
wire - news in brief
« BACK
Microtechnics - Innovation / Technology - 18.04.2019 
Jamie Paik's robots to take the stage at the TED conference
Jamie Paik, the head of EPFL's Reconfigurable Robotics Lab, will present her reconfigurable robots at the TED2019 conference in Vancouver on 18 April.
Microtechnics - Veterinary Science - 05.11.2018 
Great honor for research on vehicle emissions
This year's Swiss Aerosol Award goes to Maria Muņoz. The Empa researcher investigated the emission behavior of so-called GDI engines (gasoline-direct injection).
Environment - Microtechnics - 21.08.2018 
An underwater glider for measuring turbulence in Lake Geneva
Huge systems of rotating water masses - called gyres - form in oceans and large lakes. Two EPFL laboratories, working with the University of California, Davis, are using an underwater glider to explore one such gyre in Lake Geneva and learn more about how it affects the three-dimensional structure of the aquatic ecosystem.
Microtechnics
Results 1 - 3 of 3.
Jamie Paik, the head of EPFL's Reconfigurable Robotics Lab, will present her reconfigurable robots at the TED2019 conference in Vancouver on 18 April.
This year's Swiss Aerosol Award goes to Maria Muņoz. The Empa researcher investigated the emission behavior of so-called GDI engines (gasoline-direct injection).
Huge systems of rotating water masses - called gyres - form in oceans and large lakes. Two EPFL laboratories, working with the University of California, Davis, are using an underwater glider to explore one such gyre in Lake Geneva and learn more about how it affects the three-dimensional structure of the aquatic ecosystem.
Health - Jun 14
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy